Peter Lynch · Growth at a reasonable price (GARP)
Is Corcept Therapeutics Incorporated (CORT) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria, growth too low or price too high.
30/100
Does not fit
4/6 criteria passed
Peter Lynch's Criteria, Applied to CORT
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-0.5%
Revenue CAGR ≥ 10%
20.1%
Net margin > 0
6.2%
How CORT Scores on Other Strategies
Live Financial Snapshot
Market cap
$9.29B
P/E (TTM)
122.0x
ROIC (TTM)
-1.23%
Gross margin
98.25%
Other Peter Lynch fit reports
Frequently Asked Questions
What is CORT's Peter Lynch fit score?
CORT scores 30/100 on our Peter Lynch fit engine. Does not fit Lynch's GARP criteria, growth too low or price too high.
Does Peter Lynch actually own CORT?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends CORT.
How often is this score updated?
CORT's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends CORT.
